In vitro activity of ceftazidime-avibactam and comparators against Enterobacterales and Pseudomonas aeruginosa isolates from Central Europe and Israel, 2014–2017 and 2018

Kristóf, Katalin; Adámková, Václava; Adler, Amos; Gospodarek‐Komkowska, Eugenia; Rafilă, Alexandru; Billová, S; Możejko-Pastewka, Barbara; Kiss, F.

doi:10.1016/j.diagmicrobio.2021.115420

Cited by 10 publications

(9 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The susceptibility rates of P. aeruginosa to ceftazidime/avibactam were second highest in Central Europe (≥92%) and Poland (92%). 18 Our study with a susceptibility rate of almost 90% to ceftazidime/avibactam is consistent with the sustained trend of high activity of this antibiotic combination observed over years in Central Europe and Poland. In the study by Sader et al 1 an American 4-year study, ceftazidime/avibactam also achieved the second highest activity against P. aeruginosa isolates among all agents.…”

Section: Discussionsupporting

confidence: 90%

“…K. pneumoniae isolates were among the most abundant organisms (46% of MDR and 67% of ESBL isolates) in these phenotypes. The same trend of high ceftazidime/avibactam susceptibility is maintained in the study by Kristof et al 18 based on Central Europe, where MDR Enterobacterales had a susceptibility of almost 99% in Poland and 98% in all included countries. Similar results were obtained in the USA according to Hirsch et al, where ceftazidime/avibactam showed the highest activity against ESBL Enterobacterales with 92% susceptibility.…”

Section: Discussionsupporting

confidence: 69%

“…Among CRE isolates, most had more than one resistance mechanism: 61% of isolates were identified as carbapenemase-producing (14.3% susceptible) and 91% as non-carbapenemase-producing (47.6% susceptible). In the study by Spiliopoulou et al 18 that examined Enterobacterales collected worldwide from 2015 to 2017 as part of the surveillance program INFORM, a total of 1460 meropenem non-susceptible isolates were collected and 73% of them were susceptible to ceftazidime/avibactam. This is due to the fact that only 27% of the isolates were MBL-positive, whereas this rate was almost double in our study.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Ceftazidime/Avibactam and Other Commonly Used Antibiotics Activity Against Enterobacterales and Pseudomonas aeruginosa Isolated in Poland in 2015–2019

Zalas‐Więcek¹,

Prażyńska²,

Pojnar

et al. 2022

IDR

Self Cite

View full text Add to dashboard Cite

Purpose Infections caused by resistant Gram-negative bacteria are becoming increasingly common and now pose a serious public health threat worldwide, because they are difficult to treat due to few treatment options and they are associated with high morbidity and mortality. The combination of ceftazidime with the beta-lactamase inhibitor avibactam – seems to be the right choice in this situation. The aim of the study was to evaluate the activity of ceftazidime/avibactam and other commonly used antibiotics against Enterobacterales and Pseudomonas aeruginosa strains isolated within last years in Poland. Patients and Methods This study analyzed the antibiotic susceptibility of 1607 Enterobacterales isolates and 543 nonfermenting P. aeruginosa strains collected between 2015 and 2019 in 4 medical laboratories participating in the ATLAS (Antimicrobial Testing Leadership And Surveillance) program in Poland. Unduplicated clinically significant Enterobacterales and P. aeruginosa strains were collected from patients with respiratory, skin and musculoskeletal, genitourinary, abdominal, bloodstream or other infections (ear, eye). Results The ceftazidime/avibactam combination demonstrates the highest activity against Enterobacterales (98.9%), in both adults and children, including strains presenting MDR (multidrug-resistant) (97.5%) and ESBL (extended spectrum β-lactamase) (96.3%) phenotypes. The activity of ceftazidime/avibactam increased to 100% when only MBL (metallo-β-lactamase)-negative subset of Enterobacterales was considered. This combination also achieved the second highest activity result (89.3%) after colistin in P. aeruginosa , including isolates of MDR (65.9%) and carbapenem-resistant (CR) phenotypes (54.8%). When MBL-positive isolates were excluded, susceptibility rate of P. aeruginosa increased to 94.7%. It is worth to note that susceptibility of the examined P. aeruginosa strains to ceftazidime/avibactam was very high in children (93.3%), especially in a pediatric intensive care unit (94.2%). Conclusion Enterobacterales and P. aeruginosa included in this analysis presented high susceptibility rates to ceftazidime/avibactam. Ceftazidime/avibactam showed the highest activity against Enterobacterales strains among all antibiotics studied, both for the total population as well as for MDR phenotype and ESBL phenotype. Ceftazidime/avibactam also achieved the second highest activity result against P. aeruginosa strains (including MDR and CR phenotypes). These results are much higher when excluding MBL-positive isolates that exhibit intrinsic resistance to ceftazidime/avibactam.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionsupporting

confidence: 69%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Ceftazidime/Avibactam and Other Commonly Used Antibiotics Activity Against Enterobacterales and Pseudomonas aeruginosa Isolated in Poland in 2015–2019

Zalas‐Więcek¹,

Prażyńska²,

Pojnar

et al. 2022

IDR

Self Cite

View full text Add to dashboard Cite

show abstract

“…The antimicrobial activity of CZA and comparator agents was also assessed against a collection of 8615 isolates of Enterobacterales and P. aeruginosa from central European countries and Israel. CZA susceptibility rate was high and stable in the two time periods considered (2014–2017 and 2018), although alarming trends of resistance to comparators were detected [ 30 ]. The importance of CZA in the management of Pseudomonas infections was further increased by the voluntary manufacturing stop and global product recall of ceftolozane/tazobactam that Merk conducted from December 2020, because of compromised sterility process [ 31 ].…”

Section: Resultsmentioning

confidence: 99%

Place in Therapy of the Newly Available Armamentarium for Multi-Drug-Resistant Gram-Negative Pathogens: Proposal of a Prescription Algorithm

et al. 2021

View full text Add to dashboard Cite

The worldwide propagation of antimicrobial resistance represents one of the biggest threats to global health and development. Multi-drug-resistant organisms (MDROs), including carbapenem-resistant non-fermenting Gram-negatives and Enterobacterales, present a heterogeneous and mutating spread. Infections by MDRO are often associated with an unfavorable outcome, especially among critically ill populations. The polymyxins represented the backbone of antibiotic regimens for Gram-negative MDROs in recent decades, but their use presents multiple pitfalls. Luckily, new agents with potent activity against MDROs have become available in recent times and more are yet to come. Now, we have the duty to make the best use of these new therapeutic tools in order not to prematurely compromise their effectiveness and at the same time improve patients’ outcomes. We reviewed the current literature on ceftazidime/avibactam, meropenem/vaborbactam and cefiderocol, focusing on antimicrobial spectrum, on the prevalence and mechanisms of resistance development and on the main in vitro and clinical experiences available so far. Subsequently, we performed a step-by-step construction of a speculative algorithm for a reasoned prescription of these new antibiotics, contemplating both empirical and targeted use. Attention was specifically posed on patients with life-risk conditions and in settings with elevated prevalence of MDRO.

show abstract

“…Infectious diseases caused by P. aeruginosa , in clinical treatment, pose a significant threat to humanity [1] . Although antibiotics including the 2 nd , 3 rd , and 4 th generation cephalosporins, carbapenems, aminoglycosides, and polymyxins have been used, persistent variation led to the frequent appearance of drug‐resistant strains [2–4] . Gomphrena globose L. (globe amaranth flower), belonging to the plant family of Amaranthaceae, is used to treat dysentery and ulcer for thousands of years [5] .…”

Section: Introductionmentioning

confidence: 99%

Phytochemical and Antibacterial Constituents of Edible Globe Amaranth Flower against Pseudomonas aeruginosa

Wang

Qin

et al. 2022

Chemistry & Biodiversity

View full text Add to dashboard Cite

Globe amaranth flower, the edible inflorescence of Gomphrena globose L., was used to treat dysentery and ulcer as well as other infectious diseases caused by microbes in Southwest China, but its function and bioactive components need experimental support. In this study, phytochemical constituents and antibacterial bioactivity of globe amaranth flower against P. aeruginosa were carried out. As a result, two new (1 and 2) and eleven known (3 -11) compounds were isolated, in which compounds 4-7 displayed anti P. aeruginosa bioactivity with the minimum inhibitory concentration (MIC) from 0.008 to 0.256 mg/mL. Furthermore, with aid of the scanning electron microscope (SEM) and a superficial skin infection model in mice, the most potent compound 4 can significantly destroy the structure of bacteria in vitro and restore bacterial infection damage in vivo.

show abstract

In vitro activity of ceftazidime-avibactam and comparators against Enterobacterales and Pseudomonas aeruginosa isolates from Central Europe and Israel, 2014–2017 and 2018

Cited by 10 publications

References 9 publications

Ceftazidime/Avibactam and Other Commonly Used Antibiotics Activity Against Enterobacterales and Pseudomonas aeruginosa Isolated in Poland in 2015–2019

Ceftazidime/Avibactam and Other Commonly Used Antibiotics Activity Against Enterobacterales and Pseudomonas aeruginosa Isolated in Poland in 2015–2019

Place in Therapy of the Newly Available Armamentarium for Multi-Drug-Resistant Gram-Negative Pathogens: Proposal of a Prescription Algorithm

Phytochemical and Antibacterial Constituents of Edible Globe Amaranth Flower against Pseudomonas aeruginosa

Contact Info

Product

Resources

About